老年急性髓系白血病可测量残留病:PETHEMA-FLUGAZA 3期临床试验结果
FLUGAZA 3期试验随机283例老年AML患者接受FLUGA或5-阿扎胞苷治疗,巩固后按MFC评估的MRD≥0.01%继续治疗、<0.01%停止。
要点
- 老年AML半强化或去甲基化治疗后,MRD状态可细化CR判断。
- MFC不可测MRD者仍存广泛遗传学异常,需提高灵敏度。
核心结论
- 支持在半强化治疗或去甲基化药物治疗后评估MRD以细化完全缓解。
- 需提高MRD检测灵敏度以个体化治疗并延长老年AML患者生存。
研究设计与样本
- 3期FLUGAZA临床试验,随机283例老年AML患者接受FLUGA或5-阿扎胞苷诱导和巩固治疗。
- 巩固后按MFC评估MRD,≥0.01%继续治疗,<0.01%停止。
主要发现
- 诱导后MRD不可测者总生存更长,巩固后MRD不可测者未观察到。
- 265例中259例白血病细胞显示表型异常。
- MFC不可测MRD者的CD34祖细胞经全外显子测序仍存广泛遗传学异常。
关键数值与推荐
- MRD阈值0.01%,由多维流式细胞术(MFC)评估。
- 巩固后MRD≥0.01%继续治疗,MRD<0.01%停止治疗。
临床怎么用
- 对半强化或去甲基化治疗的老年AML患者,可用MFC评估MRD以细化CR并指导治疗时长。
局限性
- MFC不可测MRD者仍存广泛遗传学异常,提示当前灵敏度不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The value of measurable residual disease (MRD) in elderly patients with acute myeloid leukemia (AML) is inconsistent between those treated with intensive vs hypomethylating drugs, and unknown after semi-intensive therapy. We investigated the role of MRD in refining complete remission (CR) and treatment duration in the phase 3 FLUGAZA clinical trial, which randomized 283 elderly AML patients to induction and consolidation with fludarabine plus cytarabine (FLUGA) vs 5-azacitidine. After consolidation, patients continued treatment if MRD was ≥0.01% or stopped if MRD was <0.01%, as assessed by multidimensional flow cytometry (MFC). On multivariate analysis including genetic risk and treatment arm, MRD status in patients achieving CR (N = 72) was the only independent prognostic factor for relapse-free survival (RFS) (HR, 3.45; P = .002). Achieving undetectable MRD significantly improved RFS of patients with adverse genetics (HR, 0.32; P = .013). Longer overall survival was observed in patients with undetectable MRD after induction though not after consolidation. Although leukemic cells from most patients displayed phenotypic aberrancies vs their normal counterpart (N = 259 of 265), CD34 progenitors from cases with undetectable MRD by MFC carried extensive genetic abnormalities identified by whole-exome sequencing. Interestingly, the number of genetic alterations significantly increased from diagnosis to MRD stages in patients treated with FLUGA vs 5-azacitidine (2.2-fold vs 1.1-fold; P = .001). This study supports MRD assessment to refine CR after semi-intensive therapy or hypomethylating agents, but unveils that improved sensitivity is warranted to individualize treatment and prolong survival of elderly AML patients achieving undetectable MRD.
引用
- Simoes C, Paiva B, Martínez-Cuadrón D, et al. Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Blood Adv. 2021. PMID: 33560390. doi:10.1182/bloodadvances.2020003195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。